Metsera Corp - MTSR Quarterly EPS earnings growth
The quarterly EPS growth trajectory demonstrates the impact of metabolic therapy innovations on capitalization, while -327.30 shows the value of this parameter. The attractiveness of Metsera Inc (MTSR) is based on the development of weight-loss drugs that guarantee stable demand. However, geopolitical tensions may complicate international certification and component logistics.
%20Quarterly%20EPS%20earnings%20growth&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_MTSR_-_Metsera-Inc_-_Quarterly-EPS-earnings-growth "MTSR metsera.com Quarterly EPS earnings growth (02/01/2025 - 11/29/2025) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for Metsera Therapeutics (MTSR)
- share price and consensus valuation forecast:
- issuer market value details:
- balance sheet net asset value indicators:
- debt and liquidity data:
- earnings and valuation multiples indicators:
MTSR - Net Income|Projected Future Earnings Metsera Inc|MTSR - Market Cap to Earnings|Projected Price to Earnings Metsera Corp|MTSR - Company Value to Earnings Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Metsera Corp|MTSR - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Metsera|MTSR - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months metsera.com|MTSR - Earnings per share increase in current year|Earnings growth forecast for next year Metsera Inc
Analysis of all company metrics:Metsera Inc
This metric captures the dynamics of net income per share, reflecting the actual rate of change in the issuer's profitability. For Metsera Inc (MTSR), which focuses on obesity drugs, the quarterly EPS evolution verifies the effectiveness of R&D investments. The indicator's growth confirms the monetization of scientific developments with minimal ESG costs. Analysis of this chart helps avoid overpaying for the asset. A stable trend indicates the startup's financial resilience.
Competitors of Metsera Inc (MTSR)
ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|CORT (Corcept) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Rhythm Corp|Quarterly EPS earnings growth AKRO|Year-over-year earnings per share growth for the last twelve months MLTX (moonlaketx.com)|Year-over-year earnings per share growth for the last twelve months Crinetics CRNX|NewAmsterdam Pharma Company (NAMS) - Earnings per share growth in annualized terms for the last twelve months|SLNO - Year-over-year earnings per share growth for the last twelve months|FOLD: Year-over-year earnings per share growth for the last twelve months|ETNB: Quarterly EPS earnings growth|AGIO - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Structure Therapeutics Inc.|MiMedx Group Inc (MDXG) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Rezolute Corp (RZLT)|Year-over-year net earnings per share growth for the last 12 months Lexicon Corp LXRX|Year-over-year earnings per share growth for the last twelve months MBX Biosciences Inc MBX|ALT - Year-over-year net earnings per share growth for the last 12 months|Aardvark Therapeutics - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Sagimet Biosciences, Inc.|BIOA (BioAge Labs Inc.) - Year-over-year net earnings per share growth for the last 12 months|BMEA: Year-over-year earnings per share growth rate for the last twelve months|Year-over-year earnings per share growth for the last twelve months Quince Therapeutics Inc|fractyl.com (GUTS) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth VTVT|ATPC - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Pluri PLUR|Year-over-year earnings per one share growth for the last 12 months SYBX|Lipocine Inc. - Quarterly EPS earnings growth|MTNB - Quarterly EPS earnings growth|SPRB (Spruce Biosciences) - Year-over-year net earnings per share growth for the last 12 months|Galecto Inc - Year-over-year earnings per one share growth for the last 12 months|CTCX (Carmell Corp) - Quarterly EPS earnings growth|Lumos Therapeutics (LUMO) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Organovo Holdings, Inc. (ONVO)|radiuspharm.com - Year-over-year earnings per share growth for the last 12 months
